ArticleBMC public health2025
Dynamic interplay of atherogenic index and body roundness in cardio-renal-metabolic disease: a multi-state analysis.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiovascular-liver-metabolic multimorbidity: a prospective cohort study from UK Biobank.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM), atherosclerotic cardiovascular disease (CVD) and chronic kidney disease (CKD) are closely linked at epidemiological, pathophysiological, and molecular levels, forming cardio-renal-metabolic (CRM) disease. Their multimorbidity leads to multi-organ dysfunction and increased cardiovascular risk, making prevention and management crucial in clinical and public health practice.
methodsWe included 398,689 participants from UK Biobank free of CRM diseases at baseline. We used both traditional and multi-state regression model to assess the relationships between AIP-BRI —defined as the product of the atherogenic index of plasma (AIP) and the body roundness index (BRI) —and CRM diseases. Besides, we employed the restricted cubic spline (RCS) approach to visualize the dose-response relationship between AIP-BRI values and three main transition stages (baseline→first CRM diseases (FCRM), FCRM disease→ double CRM (DCRM) diseases, and DCRM diseases→triple CRM (TCRM) disease).
resultsOver a a median follow-up period of 12.7 years, 61,539 individuals developed FCRM disease. Among these, 10,714 further developed DCRM diseases, while 1,332 advanced to TCRM diseases. According to our study, AIP-BRI was significantly associated with the progression of CRM diseases in fully adjusted model (HR [95% CI]: 1.248 [1.241–1.255] for FCRM; 1.180 [1.167–1.193] for DCRM; 1.120 [1.086–1.155] for TCRM).
conclusionOur findings highlight AIP-BRI as a potentially useful composite biomarker for predicting and monitoring CRM disease progression. Its sensitivity enables early risk stratification, supporting targeted interventions to mitigate disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.